Trial Profile
A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tebentafusp (Primary) ; Tremelimumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMCgp100-201 Phase Ib/II Study
- Sponsors Immunocore
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Results assessing tebentafusp efficacy and safety in patients with metastatic cutaneous melanoma by BRAF mutation status, presented at the 48th European Society for Medical Oncology Congress.
- 26 Sep 2023 Planned End Date changed from 1 Jan 2025 to 1 Nov 2023.